TISSIUM CEO’s Vision Is To Make The Tissue Recon Label Stick

CEO Bancel Envisages TISSIUM As A Tissue Reconstruction Specialist Rather Than Simply A Provider Of A Technology

Christophe Bancel, CEO of French medtech innovator TISSIUM, has made a career in various parts of the health care products industry, identifying business opportunities, founding, directing and leading ventures, and planning for contingencies. The ex-Serono and UCB executive, who has had many other postings, is now testing his adaptability and leadership qualities by bringing a versatile class III synthetic polymer device into key markets.

Spotlight
TISSIUM Seeks Opportunity In Tissue Reconstruction

TISSIUM CEO Christophe Bancel was talking to fellow founder of the company, Jeffery Karp, when the subject turned to a Massachusetts Institute of Technology (MIT) project being developed by Maria Pereira. The technology was a biocompatible liquid polymer, and Bancel was attracted by the claim that it could suture the heart of newborns. Pereira’s technology was asserted to support faster healing and obviate the need for traditional suturing.

Seeking to take the idea further, Bancel envisioned a technology ecosystem built around the synthetic polymer, and up to four...

More from Business Strategy

More from In Vivo